MFN-driven drug price reductions in the US are unlikely to have a big impact pharma R&D spending, experts agree.

The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...

Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the ...

Sanofi acquired commercialisation rights for the radiopharmaceutical AlphaMedix from Orana Med in September 2024.

The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary ...

Johnson & Johnson’s targeted therapeutic combination, Tecvayli-Darzalex Faspro, performed better than investigator’s choice standard of care in a Phase III trial recruiting patients with R/R multiple ...

dashClinical provides instant payments that enhance trial completion and subject retention. Credit: PeopleImages/Shutterstock.com. Dash Solutions has introduced ...

The vaccine was generally well tolerated among the paediatric population, with no unexpected safety signals reported. Credit: PeopleImages/Shutterstock.com. Bavarian ...

The trial aims to determine the dosing interval, optimal dose and number of administrations for curing chronic hepatitis B. Credit: Gorodenkoff/Shutterstock.com ...

While overall survival (OS) is the king endpoint in oncology trials, it may be overshadowed by surrogates such as progression-free survival (PFS) and objective response rates (ORR) as outcomes improve ...

Skye Biosciences pipeline obesity drug, nimacimab, has failed to trigger significant weight loss as a monotherapy in a proof-of-concept Phase IIa trial. Image credit: Yellow_man / Shutterstock.com ...

Nanobiotix's JNJ-1900, which is in Phase III for HNSCC, exhibited an ORR of 69% in oesophageal cancer, potentially ...